<DOC>
	<DOCNO>NCT00412620</DOCNO>
	<brief_summary>The objective study explore safety efficacy ABT-925 involve patient meet DSM-IV-TR ( Diagnostic Statistical Manual Medical Disorders , Fourth Edition Text Revision ) criterion acute exacerbation schizophrenia schizoaffective disorder .</brief_summary>
	<brief_title>An Evaluation Safety Efficacy ABT-925 Subjects With Acute Exacerbation Schizophrenia</brief_title>
	<detailed_description>To explore safety efficacy ABT-925 treatment three different dos 6 week compare placebo subject diagnosis acute exacerbation schizophrenia schizoaffective disorder accord DSM-IV-TR criterion ( Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revision ) .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>The subject current primary diagnosis schizophrenia schizoaffective disorder ; specifically , acute exacerbation prominent `` active phase '' symptom , describe Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revision criterion ( confirm Structured Clinical Interview Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revision ) . Subjects schizophrenia may belong follow subtypes : paranoid , disorganize , catatonic , undifferentiated . The subject The Positive Negative Syndrome Scale total score great equal 60 . The subject score great 4 ( `` moderate '' ) least 2 follow 5 The Positive Negative Syndrome Scale positive symptom : delusion , conceptual disorganization , hallucinatory behavior , grandiosity , suspiciousness/persecution . The subject 18 65 year old inclusive time randomization . The subject reliable caregiver ( applicable ) identify responsible ( e.g. , family member , social worker , nurse ) support him/her ensure compliance treatment outpatient visit . In addition , subject must adequate place residence . The subject agree hospitalize duration Taper off/Washout Period least first fourteen day Doubleblind Period . The subject body mass index great 35 . The subject condition opinion investigator likely place him/her unacceptable safety risk enter study treatment ABT925 . The subject diagnosis one follow condition : another primary Axis I disorder , include schizophreniform disorder , bipolar disorder major depressive disorder ; comorbid Axis II diagnosis , include borderline personality disorder mental retardation . ( Note : diagnosis depression otherwise specify acceptable inclusion study ) . The subject diagnosis substance alcohol disorder ( abuse/dependence accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revision criterion ) , exclude nicotine , within one ( 1 ) month prior begin Screening Period , opinion investigator , disorder interfere conduct study . The subject history substanceinduced psychotic disorder previous 6 month . The subject evidence suggestive treatmentresistant schizophrenia ( i.e. , lack significant clinical improvement despite adequate course dos least two different antipsychotic medication previous 2 year ; adequate use clozapine indicate treatmentresistant schizophrenia ) . The subject serious violent , homicidal suicidal ideation opinion investigator . The subject screening QT interval correct Bazett formula interval great 430 msec male great 450 msec female . The subject 's Liver Function Tests ( Aspartate aminotransferase , Alanine aminotransferase total bilirubin level ) within normal limit screen . The subject diagnosis , history , positive serological result suggestive liver disease include limited hepatitis Gilbert 's Syndrome . The subject receive follow treatment within time period describe : mood stabilizer antidepressant 30 day prior Screening ; electroconvulsive therapy 3 month prior Screening ; clozapine 60 day prior Screening . The subject currently receive treatment oral psychotropic medication receive depot neuroleptic within one interinjection interval .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>